Vyvanse Generics Get Green Light To Enter US
More Than A Dozen Firms Receive FDA Approvals For Lisdexamfetamine Rivals
One of 2023’s most significant loss-of-exclusivity opportunities for the generics industry has come to pass, after the US FDA approved more than a dozen rivals to Takeda’s blockbuster ADHD treatment Vyvanse.
